TY - JOUR
T1 - A new look at cognitive functioning in pediatric MS
AU - the US Network of Pediatric MS Centers
AU - Krupp, Lauren B.
AU - Waubant, Emmanuelle
AU - Waltz, Michael
AU - Casper, T. Charles
AU - Belman, Anita
AU - Wheeler, Yolanda
AU - Ness, Jayne
AU - Graves, Jennifer
AU - Gorman, Mark
AU - Benson, Leslie
AU - Mar, Soe
AU - Goyal, Manu
AU - Schreiner, Teri
AU - Weinstock-Guttman, Bianca
AU - Rodriguez, Moses
AU - Tillema, Jan Mendelt
AU - Lotze, Timothy
AU - Aaen, Greg
AU - Rensel, Mary
AU - Rose, John
AU - Chitinis, Tanuja
AU - George, Allan
AU - Charvet, Leigh E.
N1 - Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Lauren B Krupp has received compensation for her role in a DSMB for Sanofi-Aventis and has received advisory board/consulting fees, travel and meal allowances, and/or research funding from Biogen, Eisai, Roche, Janssen, Gerson Lehrman, Celgene, Medergy Marketing, and Cambridge Technologies. She also serves as a non-compensated consultant for Novartis and Celgene. She has received licensing fees for the Fatigue Severity Scale from various pharmaceutical and biotechnology companies. Emmanuelle Waubant has received personal honoraria from American Academy of Neurology, American Neurologic Association, Jazz Pharmaceuticals, Emerald, and DBV. She is site PI for a Biogen and Roche trial. She volunteers on an advisory board for a Novartis trial. She is a non-remunerated advisor for clinical trial design for Roche, Serono, and Celgene. She has funding from the NIH, NMSS, PCORI, and the Race to Erase multiple sclerosis. She is co-Chief editor for MSARD Michael Waltz has nothing to disclose. Charlie Casper has nothing to disclose. Anita Belman has nothing to disclose. Yolanda Wheeler has nothing to disclose. Jayne Ness has participated in clinical trials funded by Novartis and Roche. Jennifer Graves has received grants from Biogen and personal fees from Novartis and Genentech. Mark Gorman has participated in clinical trials funded by Novartis and Biogen. Leslie Benson has received funding for a clinical trial from Biogen. Soe Mar has nothing to disclose. Manu Goyal receives research funding from Pfizer for research unrelated to the current manuscript and from the NMSS. He has received research funding as a site PI for Biogen and Novartis trials. Teri Schreiner has research support from Biogen. Bianca Weinstock-Guttman has received consulting fees from Biogen, EMD Serono, Genentech, Novartis, Mallinckrodt, and Celgene. She has received research support from Biogen, Novartis, Genentech, and Novartis. Moses Rodriguez has nothing to disclose. Jan-Mendelt Tillema has nothing to disclose. Timothy Lotze has nothing to disclose. Greg Aaen has nothing to disclose. Mary Rensel serves on the advisory board of Serono and Biogen. She has been a consultant for Biogen, and Novartis. She has received commercial research support from Biogen. She has received foundation/society research support from the National Multiple Sclerosis Society. She has received educational grants from Genzyme. She is part of the speakers’ bureau at Novartis, Genzyme. and Biogen. John Rose has research support from Teva and Biogen and unrestricted educational grants from Teva, Biogen, Novartis, and Genentech SM. Tanuja Chitnis has received research funding from Serono, Mallinckrodt, Novartis. and Verily and has participated as a consultant or advisor for Biogen, Novartis, and Sanofi-Genzyme. Allan George has nothing to disclose. Leigh E. Charvet has received consulting fees from Johnson & Johnson, serves as editorial board for Springer Healthcare https://www.neurodiem.com/ and received research funding from US Department of Defense, NIH, National MS Society, and Biogen-Idec.
Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by National Multiple Sclerosis Society (grants RG150705285 and HC-1509-06233).
Publisher Copyright:
© The Author(s), 2022.
PY - 2023/1
Y1 - 2023/1
N2 - Objective: Cognitive involvement in pediatric multiple sclerosis (MS) relative to adult MS is less defined. This study advances our understanding by measuring cognitive performances in pediatric MS, adult MS, and pediatric healthy controls. Methods: Consecutive relapsing pediatric MS participants from the United States Network of Pediatric MS Centers were compared with pediatric healthy controls and adults with relapsing MS. Participants were compared on two screening batteries: the Brief International Cognitive Assessment for MS and the Cogstate Brief Battery. Results were transformed to age-normative z scores. Results: The pediatric groups (MS vs. Healthy Controls) did not differ on either battery’s composite mean score or individual test scores (ps > 0.32), nor in the proportions impaired on either battery, Brief International Cognitive Assessment for MS (26% vs. 24%, p = 0.83); Cogstate Brief Battery (26% vs. 32%, p = 0.41). The pediatric versus adult MS group even after controlling for differences in disease duration performed better on the Brief International Cognition Assessment for MS composite (p = 0.03), Symbol Digit Modalities Test (p = 0.02), Rey Auditory Verbal Learning Test (p = 0.01), and Cogstate choice reaction time (p < 0.001). Conclusion: Pediatric MS patients do not differ from healthy pediatric controls on cognitive screens but perform better than adults with MS.
AB - Objective: Cognitive involvement in pediatric multiple sclerosis (MS) relative to adult MS is less defined. This study advances our understanding by measuring cognitive performances in pediatric MS, adult MS, and pediatric healthy controls. Methods: Consecutive relapsing pediatric MS participants from the United States Network of Pediatric MS Centers were compared with pediatric healthy controls and adults with relapsing MS. Participants were compared on two screening batteries: the Brief International Cognitive Assessment for MS and the Cogstate Brief Battery. Results were transformed to age-normative z scores. Results: The pediatric groups (MS vs. Healthy Controls) did not differ on either battery’s composite mean score or individual test scores (ps > 0.32), nor in the proportions impaired on either battery, Brief International Cognitive Assessment for MS (26% vs. 24%, p = 0.83); Cogstate Brief Battery (26% vs. 32%, p = 0.41). The pediatric versus adult MS group even after controlling for differences in disease duration performed better on the Brief International Cognition Assessment for MS composite (p = 0.03), Symbol Digit Modalities Test (p = 0.02), Rey Auditory Verbal Learning Test (p = 0.01), and Cogstate choice reaction time (p < 0.001). Conclusion: Pediatric MS patients do not differ from healthy pediatric controls on cognitive screens but perform better than adults with MS.
KW - BICAMS
KW - Cogstate
KW - Pediatric MS
KW - adult MS
KW - cognition
KW - cognitive screening
UR - http://www.scopus.com/inward/record.url?scp=85139212639&partnerID=8YFLogxK
U2 - 10.1177/13524585221123978
DO - 10.1177/13524585221123978
M3 - Article
C2 - 36189711
AN - SCOPUS:85139212639
SN - 1352-4585
VL - 29
SP - 140
EP - 149
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 1
ER -